MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.

ABSTRACT:

Background

While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending the utility of these inhibitors beyond their respective molecularly defined cancer types is challenging and will likely require biomarkers predictive of treatment response especially when used in a combination drug development setting.

Methods

The effects of PARP inhibitor Olaparib and CDK4/6 inhibitor Palbociclib on ovarian cancer cells lines including those of high-grade serous histology were examined in vitro and in vivo. We investigated the molecular mechanism underlying the synergistic effects of drug combination.

Findings

SUBMITTER: Yi J 

PROVIDER: S-EPMC6557734 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature